Format

Send to

Choose Destination
See comment in PubMed Commons below
J Addict Med. 2012 Jun;6(2):118-23. doi: 10.1097/ADM.0b013e31824fceca.

Comparisons of analgesic potency and side effects of buprenorphine and buprenorphine with ultra-low-dose naloxone.

Author information

1
Integrated Substance Abuse Programs, University of California, Los Angeles, CA 90025, USA.

Abstract

OBJECTIVES:

Opioids are the most effective pain medication available, yet concerns about their safety may limit their administration to those in need. In efforts to identify analgesics with lower potential for abuse and dependence, recent evidence suggests that combinations of opioids with ultra-low doses of the opioid antagonist naloxone may enhance the analgesic effect with increased safety. This study investigated the use of buprenorphine (0.3 mg) plus ultra-low-dose naloxone (0.02 mg) (BUP + ULDN) as compared with buprenorphine alone (0.3 mg) (BUP) for the treatment of pain.

METHODS:

In a double-blind, placebo-controlled, randomized cross-over design, 12 study participants with lingering, noncancer pain received each medication intravenously for 5 days of dosing, separated by an intertrial interval of at least 7 days to avoid possible carryover effects.

RESULTS:

We found no order effects and no differences between medications in pre- to postdose pain ratings, side effects, or adverse events.

CONCLUSIONS:

These findings suggest that BUP + ULDN is not more effective in reducing pain than BUP.

PMID:
22475985
DOI:
10.1097/ADM.0b013e31824fceca
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wolters Kluwer
    Loading ...
    Support Center